AGMB · Agomab Therapeutics NV
$14.28
+0.26 (+1.85%)
At close · Aug 26
Market Cap
$631.36M
Shares
49.25M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$14.28
Open$14.19
Day$13.58–14.60
Available close range$9.61–17.82
Avg vol 30d99K
Short int941K · 1.9% float · 7.7d
Short vol9%
DataFeb 2026–Aug 2026
The closing range uses available history since Feb 6, 2026; less than a full year is stored.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
+10%
above
RSI (14)
57
neutral
MACD trend
Negative
52-week position
57%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+15%
trailing
6-month return
0%
trailing
Relative strength
−12%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+6% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.91% of float · ▼ -21.9% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
34 holders — 13F breadth
Squeeze score
50
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
94%
annualized · 1-yr
Max drawdown
−41%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
+10%
Bullish
RSI (14)
57
Neutral
MACD trend
Negative
Bearish
52-week position
57%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+6% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.91% of float · ▼ -21.9% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
34 holders — 13F breadth
Price context
position in its available closing range
Range low $10
Now $14 · 57%
Range high $18
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AGMB
this stock
Agomab Therapeutics NV
|
$631.36M | — | — | — | 1.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.79B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AGMB | +3.9% | +15.2% | +0.5% | +11.0% | — |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +4.2% | +10.1% | -12.0% | +8.4% | — |
Key facts
CIK
2020932
CUSIP
00860C102
13F (30d)
31 filings
31 filers
Visit website
Investor relations